DNLI | Denali Therapeutics Inc. | [NASD]
Index- P/E- EPS (ttm)-2.86 Insider Own1.80% Shs Outstand136.53M Perf Week-7.11%
Market Cap3.99B Forward P/E- EPS next Y-3.44 Insider Trans-6.09% Shs Float115.72M Perf Month17.83%
Income-370.60M PEG- EPS next Q-0.84 Inst Own69.40% Short Float / Ratio7.45% / 11.68 Perf Quarter7.81%
Sales101.50M P/S39.28 EPS this Y-8.60% Inst Trans-0.77% Short Interest8.63M Perf Half Y-2.34%
Book/sh7.08 P/B4.13 EPS next Y-4.60% ROA-27.50% Target Price58.64 Perf Year21.15%
Cash/sh9.46 P/C3.09 EPS next 5Y- ROE-40.00% 52W Range20.76 - 39.43 Perf YTD5.25%
Dividend- P/FCF- EPS past 5Y-20.80% ROI-32.70% 52W High-25.77% Beta1.31
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin- 52W Low40.99% ATR1.39
Employees430 Current Ratio3.40 Sales Q/Q-16.60% Oper. Margin- RSI (14)53.94 Volatility4.23% 5.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-51.20% Profit Margin- Rel Volume0.98 Prev Close29.96
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 AMC Payout- Avg Volume738.76K Price29.27
Recom1.80 SMA201.88% SMA5013.30% SMA2002.20% Volume734,480 Change-2.30%
Date Action Analyst Rating Change Price Target Change
Jan-30-23Initiated SVB Securities Outperform $50
Dec-05-22Initiated Cowen Outperform
Nov-02-22Upgrade BTIG Research Neutral → Buy $38
Nov-02-22Initiated BofA Securities Buy $40
Jun-23-22Initiated Berenberg Buy $39
Dec-10-21Resumed Raymond James Mkt Perform
Sep-21-21Initiated Oppenheimer Outperform $85
Sep-01-21Initiated SMBC Nikko Outperform $78
May-18-21Initiated UBS Buy $70
Feb-26-21Reiterated H.C. Wainwright Buy $80 → $95
May-16-23 06:00AM
May-15-23 04:31PM
May-09-23 01:24PM
May-08-23 05:15PM
04:01PM
01:21PM Loading…
May-04-23 01:21PM
May-01-23 10:00AM
Apr-27-23 10:02AM
Apr-14-23 07:03AM
Apr-12-23 08:00AM
Apr-10-23 08:00AM
Apr-04-23 05:12AM
Mar-29-23 11:30AM
Mar-04-23 07:35AM
Feb-28-23 09:01AM
05:35PM Loading…
Feb-27-23 05:35PM
04:01PM
Feb-23-23 11:15AM
Feb-22-23 04:33PM
Feb-21-23 10:00AM
Feb-20-23 10:00AM
Feb-15-23 04:01PM
Feb-03-23 01:22PM
Jan-25-23 08:00AM
Jan-09-23 08:00AM
Jan-02-23 06:56AM
Dec-13-22 08:15AM
Dec-06-22 06:35AM
Dec-05-22 07:00AM
Nov-09-22 05:32AM
11:52AM Loading…
Nov-04-22 11:52AM
06:23AM
Nov-03-22 05:55PM
04:01PM
Nov-02-22 06:11PM
Nov-01-22 08:00AM
Oct-24-22 04:30PM
Oct-19-22 09:19PM
Oct-18-22 04:40PM
Oct-10-22 07:44AM
Oct-03-22 08:00AM
Sep-29-22 07:30AM
Sep-07-22 11:30AM
Aug-31-22 08:00AM
Aug-09-22 10:53AM
Aug-08-22 05:25PM
04:01PM
Jul-28-22 10:02AM
Jul-27-22 10:02AM
Jun-27-22 10:47AM
Jun-07-22 08:51AM
Jun-01-22 09:00AM
May-31-22 08:00AM
May-12-22 06:11AM
May-05-22 05:55PM
04:01PM
08:35AM
May-03-22 06:24AM
May-02-22 08:30AM
Apr-25-22 03:00PM
Mar-30-22 11:30AM
Mar-21-22 01:41PM
Mar-15-22 04:30PM
Mar-10-22 01:10PM
Mar-09-22 08:00AM
Mar-05-22 06:04AM
Mar-01-22 11:36AM
Feb-28-22 05:25PM
04:01PM
09:00AM
Feb-18-22 09:04AM
Feb-17-22 03:03PM
Feb-15-22 10:05AM
Feb-14-22 09:21AM
Feb-10-22 08:00AM
Feb-07-22 09:00AM
Feb-02-22 01:38PM
06:22AM
Feb-01-22 09:00AM
Jan-28-22 01:38PM
Jan-24-22 05:38PM
Jan-13-22 05:18PM
04:08PM
08:00AM
Jan-10-22 08:00AM
Dec-17-21 05:46PM
Nov-17-21 08:30AM
Nov-08-21 12:45PM
11:06AM
Nov-04-21 05:25PM
04:01PM
08:44AM
Oct-28-21 03:06PM
Oct-26-21 10:07AM
Oct-13-21 10:00AM
Oct-12-21 11:00AM
Oct-07-21 11:13AM
06:52AM
Oct-06-21 04:01PM
Sep-29-21 09:00AM
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative and lysosomal diseases in the United States and internationally. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease; TAK-594/DNL593, which is in Phase I/II clinical trials for the treatment of frontotemporal dementia-granulin; TAK-920/DNL919, which is in Phase I clinical trials for the treatment of Alzheimer's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); SAR443820/DNL788, which is in phase II clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreements with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, Genzyme Corporation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schuth Alexander O.COFO and SecretaryMay 15Option Exercise5.2810,00052,800538,691May 17 04:56 PM
Schuth Alexander O.COFO and SecretaryMay 15Sale28.6010,000286,044528,691May 17 04:56 PM
Watts Ryan J.President and CEOApr 21Option Exercise0.6824,80016,8642,264,713Apr 24 07:10 PM
Watts Ryan J.President and CEOApr 21Sale25.1524,800623,7202,239,913Apr 24 07:10 PM
Watts Ryan J.President and CEOApr 20Option Exercise0.682001362,240,113Apr 24 07:10 PM
Watts Ryan J.President and CEOApr 20Sale25.002005,0002,239,913Apr 24 07:10 PM
Schuth Alexander O.COFO and SecretaryApr 13Option Exercise5.284,89825,861533,589Apr 14 06:27 PM
Schuth Alexander O.COFO and SecretaryApr 13Sale25.044,898122,646528,691Apr 14 06:27 PM
Schuth Alexander O.COFO and SecretaryApr 12Option Exercise5.285,10226,939533,793Apr 14 06:27 PM
Schuth Alexander O.COFO and SecretaryApr 12Sale25.045,102127,754528,691Apr 14 06:27 PM
Ho CaroleChief Medical OfficerFeb 15Sale29.401,47643,394182,809Feb 17 04:20 PM
Watts Ryan J.President and CEOFeb 13Option Exercise0.6825,00017,0002,264,913Feb 15 07:01 PM
Schuth Alexander O.COFO and SecretaryFeb 13Option Exercise0.6825,00017,000524,902Feb 15 07:01 PM
Watts Ryan J.President and CEOFeb 13Sale30.0833,8151,017,2432,239,913Feb 15 07:01 PM
Schuth Alexander O.COFO and SecretaryFeb 13Sale30.093,497105,225528,691Feb 15 07:01 PM
Ho CaroleChief Medical OfficerFeb 13Sale30.102,54876,695184,285Feb 14 07:06 PM
Krognes Steve E.DirectorFeb 13Sale30.102,11963,782143,002Feb 15 07:02 PM
Watts Ryan J.President and CEOFeb 10Option Exercise0.6825,00017,0002,254,031Feb 13 07:14 PM
Watts Ryan J.President and CEOFeb 10Sale29.1025,000727,5002,229,031Feb 13 07:14 PM
Ho CaroleChief Medical OfficerFeb 10Sale29.8081824,376179,365Feb 14 07:06 PM
Watts Ryan J.President and CEOFeb 09Sale30.593,433105,0152,229,031Feb 13 07:14 PM
Schuth Alexander O.COFO and SecretaryFeb 08Sale30.891,52146,984499,902Feb 10 06:11 PM
Ho CaroleChief Medical OfficerFeb 08Sale30.881,52146,968180,183Feb 10 06:12 PM
Krognes Steve E.DirectorFeb 08Sale30.881,37742,522145,121Feb 10 06:10 PM
Schuth Alexander O.COFO and SecretaryJan 17Option Exercise5.2810,00052,800507,173Jan 19 05:09 PM
Schuth Alexander O.COFO and SecretaryJan 17Sale29.5310,000295,339497,173Jan 19 05:09 PM
Ho CaroleChief Medical OfficerJan 09Sale28.481,45941,552177,454Jan 10 04:51 PM
Ho CaroleChief Medical OfficerJan 06Sale28.671,45141,600178,913Jan 09 09:43 PM
Watts Ryan J.President and CEOJan 05Sale28.444,800136,5122,223,664Jan 09 09:41 PM
Krognes Steve E.DirectorJan 05Sale28.442,97084,467146,498Jan 09 09:42 PM
Ho CaroleChief Medical OfficerJan 05Sale28.442,63674,968180,364Jan 09 09:43 PM
Schuth Alexander O.COFO and SecretaryJan 05Sale28.442,63674,968497,173Jan 09 09:41 PM
Watts Ryan J.President and CEOJan 04Sale28.735,029144,4832,213,464Jan 05 09:07 PM
Schuth Alexander O.COFO and SecretaryJan 04Sale28.702,91283,574149,828Jan 05 09:07 PM
Ho CaroleChief Medical OfficerJan 04Sale28.692,91383,574175,500Jan 05 09:08 PM
Tessier-Lavigne MarcDirectorNov 23Sale30.4820,000609,6001,870,356Nov 28 07:30 PM
Tessier-Lavigne MarcDirectorNov 02Sale30.3311,252341,2731,890,356Nov 03 05:37 PM
Tessier-Lavigne MarcDirectorNov 01Sale30.208,748264,1901,901,608Nov 03 05:37 PM
Schuth Alexander O.COFO and SecretaryOct 07Option Exercise0.6820,00013,600487,471Oct 12 04:05 PM
Tessier-Lavigne MarcDirectorSep 28Sale30.8220,000616,3041,910,356Sep 30 04:50 PM
Tessier-Lavigne MarcDirectorAug 23Sale31.6120,000632,2821,930,356Aug 25 06:11 PM
Ho CaroleChief Medical OfficerAug 23Sale31.982,42477,520170,663Aug 25 06:10 PM
Schuth Alexander O.COFO and SecretaryAug 19Sale33.222,57685,575467,471Aug 23 04:46 PM
Ho CaroleChief Medical OfficerAug 19Sale33.222,57685,575173,087Aug 23 04:45 PM
Watts Ryan J.President and CEOAug 19Sale33.222,40479,8612,202,993Aug 23 04:48 PM
Krognes Steve E.DirectorAug 19Sale33.222,25374,845149,468Aug 23 04:47 PM
Tessier-Lavigne MarcDirectorJul 25Sale35.6120,000712,1101,950,356Jul 27 06:49 PM
Krognes Steve E.DirectorJul 19Option Exercise0.6862,50042,500151,721Jul 21 07:36 PM